Moreover, we speculate that CVT-6883 (a selective A2BAR antagonist) would reduce TGF-β1-mediated fibroblast proliferation and differentiation into myofibroblasts, and ultimately attenuate MWCNT-induced lung fibrosis. Here, TGFB1 is linked to pulmonary fibrosis.